Clinical Trials
3 trialsNCT04729959 2026-04-01
Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04370834 2025-02-04
Tocilizumab for Patients With Cancer and COVID-19 Disease
National Cancer Institute (NCI)
Phase 2 Terminated
NCT01441063 2020-10-27
Tocilizumab for KSHV-Associated Multicentric Castleman Disease
National Institutes of Health Clinical Center (CC)
Phase 2 Completed